Optimization of preoperative chemotherapy for breast cancer using whole genome sequencing -prediction of pathological complete response and exploration of a novel target for patients with non-pathological complete response
- Conditions
- Breast Cancer
- Registration Number
- JPRN-UMIN000051093
- Lead Sponsor
- West Japan Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 240
Not provided
1. Patients with a history of invasive malignancy within the past 3 years from the time consent was obtained. 2. Have an active infection requiring systemic treatment. 3. Have poorly controlled diabetes mellitus or hypertension. 4. Patients with unstable angina, myocardial infarction within 6 months, or clinically significant arrhythmia requiring treatment. 5. Congestive heart failure, poorly controlled valvular heart disease, dilated cardiomyopathy, or hypertrophic cardiomyopathy consistent with New York Heart Association (NYHA) Classification II or higher. 6. Receiving continuous systemic administration of steroids " exceeding 10mg/day of prednisolone equivalent"or immunosuppressive agents. 7. Other cases deemed inappropriate by the physician in charge.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Identify genomic and immunological factors that correlate with pCR in preoperative treatment
- Secondary Outcome Measures
Name Time Method